Dacomitinib

The Basics

What is Dacomitinib?

Used to treat non-small cell lung cancer.

Brand names for Dacomitinib

Vizimpro

How Dacomitinib is classified

Antineoplastic Agents, Enzyme Inhibitors, Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors

Dacomitinib During Pregnancy

Dacomitinib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Dacomitinib while pregnant

N/A

Taking Dacomitinib While Breastfeeding

What are recommendations for lactation if you're taking Dacomitinib?

No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 70 hours, the manufacturer recommends that breastfeeding be discontinued during dacomitinib therapy and for at least 17 days after the last dose.

Maternal / infant drug levels

No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 70 hours, the manufacturer recommends that breastfeeding be discontinued during dacomitinib therapy and for at least 17 days after the last dose.

Possible effects of Dacomitinib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Dacomitinib

None listed